Cannabis and amyotrophic lateral sclerosis: Hypothetical and practical applications, and a call for clinical trials

American Journal of Hospice and Palliative Medicine

Volumn 27, Issue 5, 2010, Pages 347-356

  Carter, Gregory T ^a   Abood, Mary E ^b   Aggarwal, Sunil K ^c   Weiss, Michael D ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

amyotrophic lateral sclerosis; cannabis; clinical trials; endocannabinoids; motor neuron disease

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CANNABINOID; CANNABIS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; METHODOLOGY; MOTONEURON; MOUSE; NERVE DEGENERATION; PHYTOTHERAPY; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CANNABINOIDS; CANNABIS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NERVE DEGENERATION; PHYTOTHERAPY;

EID: 77955351674     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909110369531     Document Type: Article

References (143)

1. Qureshi M., Schoenfeld DA, Paliwal Y., Shui A., Cudkowicz ME The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler. 2009;10(5-6):324-331.
2. Miller RG, Jackson CE, Kasarskis EJ,et al.Quality Standards subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227-1233.
3. Miller RG, Jackson CE, Kasarskis EJ,et al.Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218-1226.
4. Gurney ME, Pu H., Chiu AY,et al.Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994; 264:1772-1775.
5. Weiss MD, Ravits JM, Schuman N., Carter GT A 4V superoxide dismutase mutation in apparently sporadic ALS resembling neuralgic amyotrophy. Amyotroph Lateral Scler. 2006;7(1):61-63.
6. Suzuki M., Klein S., Wetzel EA,et al.Acute glial activation by stab injuries does not lead to overt damage or motor neuron degeneration in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. Exp Neurol. 2010;221(2):346-352.
7. Boillée S., Vande Velde C., Cleveland DW ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006; 52(1):39-59.
8. Chen Y., Meininger V., Guillemin GJ Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. Cent Nerv Syst Agents Med Chem. 2009;9(1):32-39.
9. Van Damme P., Robberecht W. Recent advances in motor neuron disease. Curr Opin Neurol. 2009;22(5):486-492.
10. Miller RG, Mitchell JD, Lyon M., Moore DH Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;24(1):CD001447.
11. Distad BJ, Meekins GD, Liou LL, Weiss MD, Carter GT, Miller RG Drug therapy in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008;19(3):633-651.
12. Distad BJ, Weiss MD Neurotrophic factors in neuromuscular disease. Phys Med Rehabil Clin N Am. 2005;16(4):999-1014.
13. Kim K., Moore DH, Makriyannis A., Abood ME AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol. 2006;542(1-3):100-105.
14. Shoemaker JL, Seely KA, Reed RL, Crow JP, Prather PL The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem. 2007; 101(1):87-98.
15. Raman C., McAllister SD, Rizvi G., Patel SG, Moore DH, Abood ME Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(1):33-39.
16. Weydt P., Hong S., Witting A., Möller T., Stella N., Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(3):182-184.
17. Rossi S., De Chiara V., Musella A.,et al.Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;19(1):1-8.
18. Bilsland LG, Dick JR, Pryce G.,et al.Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006;20(7):1003-1005.
19. Bilsland LG, Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr Pharm Des. 2008;14(23): 2306-2316.
20. Zhao P., Ignacio S., Beattie EC, Abood ME Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity. Eur J Neurosci. 2008;27(3):572-579.
21. Witting A., Weydt P., Hong S., Kliot M., Moller T., Stella N. Endocannabinoids accumulate in spinal cord of SOD1 transgenic mice. J Neurochem. 2004;89(6):1555-1557.
22. Carter GT, Rosen BS Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2001;18(4): 264-270.
23. Gelinas D., Miller RG, Abood ME A pilot study of safety and tolerability of Delta 9-THC (Marinol) treatment for ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3(suppl 1):23.
24. Amtmann D., Weydt P., Johnson KL, Jensen MP, Carter GT Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004;21:95-104.
25. Carter GT, Weydt P. Cannabis: old medicine with new promise for neurological disorders. Curr Opin Investig Drugs. 2002; 3(3):437-440.
26. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C., Morrill R., Mayer JD Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153-168.
27. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C., Morrill R., Mayer JD Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State. J Opioid Manag. 2009;5(5):257-286.
28. Russo EB Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett. 2008;29(2):192-200.
29. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2010;9:59-61.
30. Adams IB, Martin BR Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585-1614.
31. Romero J., Orgado JM Cannabinoids and neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2009;8(6):440-450.
32. Hampson AJ, Grimaldi M., Axelrod J., Wink D. Cannabidiol. Delta9 tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A. 1998;95(14):8268-8273.
33. Hampson AJ, Grimaldi M., Lolic M., Wink D., Rosenthal R., Axelrod J. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci. 2000;899:274-282.
34. Nagayama T., Sinor AD, Simon RP,et al.Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci. 1999;19(8):2987-2995.
35. Abood ME Molecular biology of cannabinoid receptors. Handb Exp Pharmacol. 2005;168:81-115.
36. McAllister SD, Hurst DP, Barnett-Norris J., Lynch D., Reggio PH, Abood ME Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem. 2004;279(46):48024-48037.
37. McAllister SD, Chan C., Taft RJ,et al.Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol. 2005;74(1):31-40.
38. Kapur A., Samaniego P., Thakur GA, Makriyannis A., Abood ME Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. J Pharmacol Exp Ther. 2008;325(1):341-348.
39. Gehani NC, Nalwalk JW, Razdan RK,et al.Significance of cannabinoid CB1 receptors in improgan antinociception. J Pain. 2007;8(11):850-860.
40. Anavi-Goffer S., Fleischer D., Hurst DP,et al.Helix 8 Leu in the CB1 cannabinoid receptor contributes to selective signal transduction mechanisms. J Biol Chem. 2007;282(34):25100-25113.
41. McAllister SD, Rizvi G., Anavi-Goffer S.,et al.An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem. 2003; 46(24):5139-5152.
42. McAllister SD, Tao Q., Barnett-Norris J.,et al.A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem Pharmacol. 2002;63(12):2121-2136.
43. Abood ME, Rizvi G., Sallapudi N., McAllister SD Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett. 2001;309(3):197-201.
44. Panikashvili D., Simeonidou C., Ben Shabat S.,et al.An endogenous cannabinoid (2 AG) is neuroprotective after brain injury. Nature. 2001;413(6855):527-531.
45. Chen Y., Buck J. Cannabinoids protect cells from oxidative cell death: a receptor independent mechanism. J Pharmacol Exp Ther. 2000;293(3):807-812.
46. Eshhar N., Striem S., Biegon A. HU 211, a non psychotropic cannabinoid, rescues cortical neurones from excitatory amino acid toxicity in culture. Neuroreport. 1993;5(3):237-240.
47. Guzman M., Sanchez C., Galve-Roperth I. Control of the cell survival/death decision by cannabinoids. J Mol Med. 2001;78:613-625.
48. Maenpaa H., Mannerstrom M., Toimela T., Salminen L., Saransaari P., Tahti H. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol. 2002;91(3):116-122.
49. Klein TW, Lane B., Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 2000; 225(1):1-8.
50. Pertwee RG Cannabinoid receptor ligands: clinical and neuro-pharmacological considerations, relevant to future drug discovery and development. Expert Opin Investig Drugs. 2000;9(7): 1553-1571.
51. De Laurentiis A., Fernández Solari J., Mohn C., Zorrilla Zubilete M., Rettori V. Endocannabinoid system participates in neuroendocrine control of homeostasis. Neuro immuno modulation. 2010;17(3):153-156.
52. Di Marzo V., Bisogno T., De Petrocellis L. Endocannabinoids: new targets for drug development. Curr Pharm Des. 2000;6(13): 1361-1380.
53. González S., Bisogno T., Wenger T.,et al.Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland. Biochem Biophys Res Commun. 2000;270(1):260-266.
54. López HH, Webb SA, Nash S. Cannabinoid receptor antagonism increases female sexual motivation. Pharmacol Biochem Behav. 2009;92(1):17-24.
55. Nagarkatti P., Pandey R., Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-1349.
56. Mouslech Z., Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinol Lett. 2009;30(2):153-179.
57. Wegener N., Koch M. Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry. 2009; 42(suppl 1):S79-S86.
58. De Petrocellis L., Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009;23(1):1-15.
59. Goodfellow CE, Glass M. Anandamide receptor signal transduction. Vitam Horm. 2009;81:79-110.
60. Pertwee RG Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 2008; 13(2):147-159.
61. Cencioni MT, Chiurchiù V., Catanzaro G.,et al.Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One. 2010;5(1):e8688.
62. Pasquariello N., Catanzaro G., Marzano V.,et al.Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis. J Biol Chem. 2009 23;284(43):29413-29426.
63. Pandey R., Mousawy K., Nagarkatti M., Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res. 2009;60(2): 85-92.
64. Parolaro D., Massi P., Rubino T., Monti E. Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids. 2002;66(2-3):319-332.
65. Mato S., Alberdi E., Ledent C., Watanabe M., Matute C. CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes. Glia. 2009;57(3):295-306.
66. Anand P., Whiteside G., Fowler CJ, Hohmann AG Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255-266.
67. Maenpaa H., Mannerstrom M., Toimela T., Salminen L., Saransaari P., Tahti H. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. Pharmacol Toxicol. 2002;91(3):116-122.
68. Traynor BJ, Bruijn L., Conwit R.,et al.Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006; 67(1):20-27.
69. Lee ES, Yin Z., Milatovic D., Jiang H., Aschner M. Estrogen and tamoxifen protect against Mn-induced toxicity in rat cortical primary cultures of neurons and astrocytes. Toxicol Sci. 2009; 110(1):156-167.
70. Gerra G., Zaimovic A., Gerra ML,et al.Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov. 2010; 5(1):46-52.
71. Fischedick JT, Glas R., Hazekamp A., Verpoorte R. A qualitative and quantitative HPTLC densitometry method for the analysis of cannabinoids in Cannabis sativa L. Phytochem Anal. 2009;20(5): 421-426.
72. Izzo AA, Borrelli F., Capasso R., Di Marzo V., Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci. 2009;30(10): 515-527.
73. Turcotte D., Le Dorze JA, Esfahani F., Frost E., Gomori A., Namaka M. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. Expert Opin Pharmacother. 2010;11(1):17-31.
74. Akinshola BE, Chakrabarti A., Onaivi ES In vitro and in vivo action of cannabinoids. Neurochem Res. 1999;24(10): 1233-1240.
75. Agurell S., Halldin M., Lindgren JE,et al.Pharmacokinetics and metabolism of delta 1 tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38(1):21-43.
76. Borrelli F., Aviello G., Romano B.,et al.Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med. 2009;87(11):1111-1121.
77. Zanelati TV, Biojone C., Moreira FA, Guimarães FS, Joca SR Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010;159(1):122-128.
78. Jones NA, Hill AJ, Smith I.,et al.Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569-577.
79. Krivickas LS, Carter GT Amyotrophic lateral sclerosis. J Spinal Cord Med. 2002;25(4):274-276.
80. Weiss MD, Weydt P., Carter GT Current pharmacological management of amyotrophic lateral sclerosis and a role for rational polypharmacy. Expert Opin Pharmacother. 2004;5(4):735-746.
81. Maccarrone M., Finazzi-Agro A. The endocannabinoid system,anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ. 2003;10:946-955.
82. Burgess RW, Cox GA, Seburn KL Neuromuscular disease models and analysis. Methods Mol Biol. 2010;602:347-393.
83. Weiss MD, Carter GT The state of the science of all motor neuron diseases. Phys Med Rehabil Clin N Am. 2008;19(3):xix-xx.
84. Zhao P., Leonoudakis D., Abood ME, Beattie EC Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology. 2010;58(2):551-558.
85. Yiangou Y., Facer P., Durrenberger P.,et al.COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12.
86. Kapur A., Zhao P., Sharir H.,et al.Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem. 2009;284(43):29817-29827.
87. Zhao P., Leonoudakis D., Abood ME, Beattie EC Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. Neuropharmacology. 2010;58(2):551-558.
88. Zhang M., Adler MW, Abood ME, Ganea D., Jallo J., Tuma RF CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res. 2009;78(1):86-94.
89. Wallace MJ, Martin BR, DeLorenzo RJ Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002;452:295-301.
90. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129-137.
91. Baker D., Pryce G., Giovannoni G., Thompson AJ The therapeutic potential of cannabis. Lancet Neurology. 2003;2:291-298.
92. Mechoulam R., Panikashvili D., Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8:58-61.
93. Richardson JD, Kilo S., Hargreaves KM Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 1998;75:111-119.
94. Abresch RT, Seyden NK, Wineinger MA Quality of life: issues for persons with neuromuscular diseases. Phys Med Rehabil Clin N Am. 1998;9(1):233-248.
95. Mayadev AS, Weiss MD, Distad BJ, Krivickas LS, Carter GT The amyotrophic lateral sclerosis center: a model of multidisciplinary management. Phys Med Rehabil Clin N Am. 2008;19(3):619-631.
96. Carter GT, Butler LM, Abresch RT, Ugalde VO Expanding the role of hospice in the care of amyotrophic lateral sclerosis. Am J Hosp Palliat Med. 1999;16(6):707-710.
97. Brettschneider J., Kurent J., Ludolph A., Mitchell JD Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2008;(3):CD005226.
98. Bromberg MB Quality of life in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008;19(3):591-605.
99. Meng ID, Manning BH, Martin WJ, Fields HL An analgesia circuit activated by cannabinoids. Nature. 1998;395(6700):381-383.
100. Zeltser R., Seltzer Z., Eisen A., Feigenbaum JJ, Mechoulam R. Suppression of neuropathic pain behavior in rats by a non-psychotropic synthetic cannabinoid with NMDA receptor-blocking properties. Pain. 1991;47(1):95-103.
101. Elikottil J., Gupta P., Gupta K. The analgesic potential of cannabinoids. J Opioid Manag. 2009;5(6):341-357.
102. Karst M., Wippermann S. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin Investig Drugs. 2009;18(2):125-133.
103. Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK Structure activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore. J Med Chem. 1996;39(2):471-497.
104. Agurell S., Halldin M., Lindgren JE,et al.Pharmacokinetics and metabolism of delta 1 tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 1986;38(1):21-43.
105. Johansson E., Halldin MM, Agurell S., Hollister LE, Gillespie HK Terminal elimination plasma half life of delta 1 tetrahydrocannabinol (delta 1 THC) in heavy users of marijuana. Eur J Clin Pharmacol. 1989;37(3):273-277.
106. Martín-Sánchez E., Furukawa TA, Taylor J., Martin JL Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009; 10(8):1353-1368.
107. Richardson JD Cannabinoids modulate pain by multiple mechanisms of action. J Pain. 2000;1(1):1-20.
108. Meinck HM, Schonle PW, Conrad B. Effects of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 1989; 263(2):120-122.
109. Greenberg HS, Weiness AS, Pugh JE Short term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994;55:324-328.
110. Fitzgerald PB, Williams S., Daskalakis ZJ A transcranial magnetic stimulation study of the effects of cannabis use on motor cortical inhibition and excitability. Neuropsychopharmacology. 2009;34(11):2368-2375.
111. Lichtman AH, Martin BR Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther. 1991; 258:517-523.
112. Collin C., Davies P., Mutiboko IK, Ratcliffe S. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290-296.
113. Carter GT, Johnson ER, Bonekat HW, Lieberman JS Laryngeal diversion in the treatment of intractable aspiration in motor neuron disease. Arch Phys Med Rehabil. 1992; 73(7):680-682.
114. Rosenfeld J., Ellis A. Nutrition and dietary supplements in motor neuron disease. Phys Med Rehabil Clin N Am. 2008;19(3): 573-589.
115. Greenberg I., Kuehnle J., Mendelson JH, Bernstein JG Effects of marijuana use on body weight and caloric intake in humans. Psycho pharmacol. 1976;49:79-84.
116. Nelson K., Walsh D., Deeter P., Sheehan F. A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10(1):14-18.
117. Gieringer DH, Rosenthal E., Carter GT Marijuana medical handbook: practical guide to the therapeutic uses of marijuana. Oakland, CA: Quick American Press; 2008:39-109.
118. Abrams DI, Vizoso HP, Shade SB, Jay C., Kelly ME, Benowitz NL Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007;82(5): 572-578.
119. Pomahacova B., Van der Kooy F., Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol. 2009;21(13):1108-1112.
120. Carter GT, Ugalde VO Medical marijuana: Emerging applications for the management of neurological disorders. Phys Med Rehabil Clin N Am. 2004; 15(4):943-954.
121. Carter GT, Weydt P., Kyashna-Tocha M., Abrams DI Medicinal cannabis: rational guidelines for dosing. IDrugs. 2004;7(5): 464-470.
122. Aggarwal SK, Kyashna-Tocha M., Carter GT Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State. MedGenMed. 2007; 9(3):52-53.
123. Kirk R. Clinical trials in CNS-SMi's eighth annual conference. IDrugs. 2010;13(2):66-69.
124. Al-Shamahi A., Kirkham K., Hookes L. Society for Neuroscience - 39th Annual Meeting. Part 1 - Novel therapies for the treatment of CNS disorders and pain. IDrugs. 2009;12(12):731-733.
125. Al-Shamahi A., Kirkham K., Hookes L. Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases. IDrugs. 2009;12(12): 734-737.
126. Macauley D., Al-Shamahi A. Society for Neuroscience-38th Annual Meeting-Data for therapeutics for CNS diseases and disorders. IDrugs. 2009;12(1):17-19.
127. Gwinn K., Corriveau RA, Mitsumoto H.,et al,for ALS Research Group. Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One. 2007;2(12):e1254.
128. Weydt P., Weiss MD, Moller T., Carter GT Neuroinflammation as a therapeutic target in amyotrophic lateral sclerosis. Curr Opin Investig Drugs. 2002;3(12):1720-1724.
129. Robson P. Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol. 2005;168:719-756.
130. McCarberg BH, Barkin RL The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther. 2007; 14(5):475-483.
131. Gerra G., Zaimovic A., Gerra ML,et al.Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov. 2010; 5(1):46-52.
132. Barchet TM, Amiji MM Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv. 2009;6(3):211-225.
133. Kanehisa M. Representation and analysis of molecular networks involving diseases and drugs. Genome Inform. 2009;23(1): 212-213.
134. Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fatty Acids. 2002; 66(2-3):93-99.
135. Gerdeman GL, Lovinger DM Emerging roles for endocannabinoids in long-term synaptic plasticity. Br J Pharmacol. 2003; 140(5):781-789.
136. Russo EB History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614-1648.
137. El Sohly MA, Wachtel SR, de Wit H. Cannabis versus THC: response to Russo and McPartland. Psycho pharmacol. 2003; 165(4):433-434.
138. Abrams DI, Jay CA, Shade SB,et al.Cannabis in painful HIVassociated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515-521.
139. Wilsey B., Marcotte T., Tsodikov A.,et al.A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008; 9(6):506-521.
140. Ellis RJ, Toperoff W., Vaida F.,et al.Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacol. 2009;34(3):672-680.
141. Rog DJ, Nurmikko TJ, Friede T., Young CA Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
142. Benatar M., Kurent J., Moore DH Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2009;1:CD006153.
143. Valdmanis PN, Daoud H., Dion PA, Rouleau GA Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep. 2009;9(3):198-205.